- Policy
- Taiwanese PharmaEssentia got a business license
- by Lee, Tak-Sun Nov 5, 2021 05:24am
- PharmaEssentia, a Korean subsidiary of PharmaEssentia, a Taiwanese pharmaceutical company, has obtained a drug business license. The first CEO of PharmaEssentia in Korea is Haksun Moon, former representative of Novartis Korea. The MFDS granted PharmaEssentia Korea a drug business license as of the 4th. The first factory is located on the 1
- Policy
- Gov needs to maintain patient benefits to the public
- by Lee, Jeong-Hwan Nov 5, 2021 05:23am
- Starting next year, the Korea Organization For Patient Group expressed regret to the MOHW and the HIRA, which triggered anxiety and confusion among cancer patients by announcing plans to exclude second-tier anticancer drugs from the coverage. The Korea Organization For Patient Group urged the MOHW and the HIRA to give confidence in ensurin
- Policy
- The HIRA proceeds to improve the mediation system
- by Lee, Hye-Kyung Nov 4, 2021 05:56am
- The MOHW requests the promotion of research services for effective system operation. Improvement of the adjustment application system will be carried out to raise the upper limit of -reimbursed drugs. The HIRA recently made an open bid for a "request for research proposal on how to improve the drug adjustment application system" and announced
- Policy
- MFDS to support Phase III trials of domestic COVID-19 Txs
- by Lee, Tak-Sun Nov 4, 2021 05:56am
- The Ministry of Food and Drug Safety has been supporting domestic companies that have entered Phase III trials for their domestic COVID-19 treatments through its ‘Development-focused Support Council.' The three items currently approved for Phase III trials and supported by the Support Council are: Chong Kun Dang’s ‘Nafabeltan (nafamos
- Policy
- NA asks NHIS to introduce the reference pricing system
- by Lee, Hye-Kyung Nov 4, 2021 05:55am
- The National Assembly raised the opinion that a reference pricing system should be introduced to induce price competition between generic drugs and encourage the use of cheaper generics. NA member Youngseok Seo of the Democratic Party of Korea inquired on introducing the reference pricing system to normalize the generic market and reduce
- Policy
- Refund RSA may be set higher than the lowest price
- by Lee, Jeong-Hwan Nov 4, 2021 05:55am
- The HIRA said that the cost-effectiveness evaluation criteria for omitted drugs that submit economic evaluation data are less than 80% of the lowest A7 adjustment price. It also explained that the economical evaluation drug can be integrated into a risk-sharing system (RSA), which can set the indicator price higher than the lowest A7 price in
- Policy
- Finding a system that suppresses the use of expensive drugs
- by Kim, Jung-Ju Nov 4, 2021 05:55am
- The HIRA said it will seek a system to prevent indiscriminate use of expensive drugs and manage expensive products that have already been registered. The HIRA also said it would make it mandatory to inspect the use of DUR systems for safe use. The HIRA submitted a recent written answer to Seo Young-seok, a member of the Democratic Party o
- Policy
- HIRA deletes GDP phrase but maintains current ICER threshold
- by Lee, Hye-Kyung Nov 3, 2021 05:47am
- The industry has requested an explanation on why the Health Insurance Review and Assessment Service deleted the ‘reference to per GDP capita’ phrase in its ICER threshold regulations. On the 23rd, HIRA disclosed the ‘Detailed Evaluation Criteria for drugs subject to negotiation such as new drugs, etc.,' and changed the ICER threshold crite
- Policy
- The new system doesn't stop benefits for anticancer drugs
- by Lee, Jeong-Hwan Nov 3, 2021 05:47am
- The MOHW promised to operate a system that does not cause damage to patients due to the suspension of high-priced anticancer drug benefits due to the expansion of the new comprehensive insurance system. The plan is to review and operate measures to ensure continuity of treatment for existing patients taking expensive anticancer drugs such as
- Policy
- The number of licenses for Rx drugs in October exceeded 100
- by Lee, Tak-Sun Nov 3, 2021 05:46am
- The number of monthly permits increased again as the generic release of AstraZeneca's diabetes combination drug "Xigduo XR (Metformin+Dapagliflozin Propanediol Hydrate)" first appeared in October. As many as 31 generics for Xigduo XR were approved in October, all of which are consignment items manufactured by Richwood Trading Company. It
